Valuation : TegoScience Inc.

Market Cap 5.93TCr 4.3Cr 3.71Cr 3.48Cr 3.17Cr 5.98Cr 411.42Cr 6Cr 41Cr 16Cr 207.68Cr 16Cr 16Cr 688.64Cr P/E 2024
29.9x
P/E 2025 -18.6x
Enterprise Value 2.4TCr 1.74Cr 1.5Cr 1.41Cr 1.29Cr 2.42Cr 166.74Cr 2.43Cr 17Cr 6.52Cr 84Cr 6.55Cr 6.41Cr 279.08Cr EV / Sales 2024
11x
EV / Sales 2025 16x
Free-Float
51.46%
Yield 2024 *
-
Yield 2025 -
19/05 TegoScience Inc. agreed to acquire 95.77% stake in PNP Pharm Co., Ltd. for KRW 3.7 billion. CI
27/25/27 TegoScience Inc. announced that it has received KRW 27 billion in funding CI
23/25/23 TegoScience Inc. announced that it expects to receive KRW 27 billion in funding CI
18/23/18 TegoScience Inc.(KOSDAQ:A191420) dropped from S&P Global BMI Index CI
22/23/22 TegoScience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
15/22/15 TegoScience Inc.'s Equity Buyback announced on March 16, 2020, has expired. CI
15/21/15 TegoScience Inc.'s Equity Buyback Plan Extended till September 15, 2021. CI
15/20/15 TegoScience Inc.'s Equity Buyback Plan Extended till March 15, 2021. CI
19/20/19 Tranche Update on TegoScience Inc.'s Equity Buyback Plan announced on March 16, 2020. CI
16/20/16 TegoScience Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares. CI
16/20/16 Tego Science, Inc. authorizes a Buyback Plan. CI
21/16/21 TegoScience Inc. announced that it has received KRW 15 billion in funding from Korea Investment Capital Co., Ltd, LIG Investment & Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm CI
19/16/19 TegoScience Inc. announced that it expects to receive KRW 15 billion in funding from Korea Investment Capital Co., Ltd, LIG Investment & Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm CI
1 day-1.59%
1 week-1.85%
Current month+17.99%
1 month+32.32%
3 months-24.39%
6 months-43.00%
Current year-54.54%
1 week 7,000
Extreme 7000
7,900
1 month 5,840
Extreme 5840
8,970
Current year 5,230
Extreme 5230
16,500
1 year 5,230
Extreme 5230
19,370
3 years 5,230
Extreme 5230
26,100
5 years 5,230
Extreme 5230
28,700
10 years 5,230
Extreme 5230
73,500
Manager TitleAgeSince
Chief Executive Officer 60 20/03/2001
Corporate Officer/Principal 53 -
Comptroller/Controller/Auditor 65 -
Director TitleAgeSince
Director/Board Member 60 20/03/2001
Director/Board Member 63 20/03/2001
Director/Board Member 53 01/05/2001
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%-1.85%-59.77%-22.41% 4.3Cr
-1.67%-4.78%+36.76%-4.34% 7.93TCr
-0.90%+2.39%-19.06%-35.50% 5.92TCr
-3.35%-4.92%+472.81%+18.97% 5.51TCr
-6.78%-4.19%-3.45%+28.35% 4.99TCr
-2.43%-2.35%+8.33%+160.40% 4.79TCr
-1.35%+0.79%+65.25%-18.47% 3.23TCr
-2.64%-2.69%+46.99%+92.55% 2.52TCr
-0.09%+4.98%+11.00%+199.86% 2.39TCr
-0.34%+1.35%+62.33%+122.21% 1.69TCr
Average -2.11%-1.06%+62.12%+54.16% 3.9TCr
Weighted average by Cap. -2.42%-2.05%+83.83%+41.75%

Financials

2024 2025
Net sales 675.91Cr 49.04L 42.26L 39.62L 36.17L 68.14L 47Cr 68.35L 4.7Cr 1.83Cr 24Cr 1.84Cr 1.8Cr 78Cr 594.07Cr 43.1L 37.14L 34.82L 31.79L 59.89L 41Cr 60.08L 4.13Cr 1.61Cr 21Cr 1.62Cr 1.58Cr 69Cr
Net income 334.97Cr 24.3L 20.94L 19.64L 17.92L 33.77L 23Cr 33.88L 2.33Cr 90.89L 12Cr 91.25L 89.26L 39Cr -701.24Cr -50.88L -43.84L -41.11L -37.52L -70.69L -49Cr -70.92L -4.88Cr -1.9Cr -25Cr -1.91Cr -1.87Cr -81Cr
Net Debt -2.56TCr -1.86Cr -1.6Cr -1.5Cr -1.37Cr -2.58Cr -177.4Cr -2.59Cr -18Cr -6.94Cr -90Cr -6.97Cr -6.82Cr -296.93Cr -3.53TCr -2.56Cr -2.21Cr -2.07Cr -1.89Cr -3.56Cr -244.68Cr -3.57Cr -25Cr -9.57Cr -123.51Cr -9.61Cr -9.4Cr -409.55Cr
Logo TegoScience Inc.
Tego Science Inc is a Korea-based company principally engaged in the manufacture and distribution of biopharmaceuticals. The Company is principally engaged in the research, development, manufacture and distribution of cell therapy products used for the treatment of third-degree and severe burns, deep second-degree burns, diabetic foot ulcers and under-eye wrinkles. The Company is engaged in the manufacture and sale of artificial skins used for testing the efficacy and safety of pharmaceuticals and cosmetics as well as for screening new drugs. In addition, the Company is engaged in the provision of biopharmaceutical contract manufacturing and development organization (CDMO) services and experimental services. The Company is also engaged in the property rental.
Employees
-
Date Price Change Volume
28/26/28 ₩7,410.00 -1.59% 7,036
27/26/27 ₩7,530.00 -0.66% 1,498
26/26/26 ₩7,580.00 -0.26% 912
25/26/25 ₩7,600.00 +2.70% 1,394
24/26/24 ₩7,400.00 -1.99% 4,316
  1. Stock Market
  2. Stocks
  3. A191420 Stock